The first heart attack patent treated with the gel was released from hospital.
BiolineRX Ltd. (TASE:BLRX) today announced that the first heart-attack patient treated with the company's heart support gel, BL-1040, was released from the Heidelberg University Hospital in Germany. This was the first patient treated as part of the Phase I/II human clinical trial to test the safety and feasibility of the treatment for the US Food and Drug Administration (FDA).
BiolineRX rose 14% today to give a market cap of NIS 161 million.
The clinical trial aims to include 30 patients in Germany, Belgium, and Israel. The company expects to complete the trial by the end of 2008. BL-1040 is a liquid polymer that transforms into a gel-like scaffold after being administered to damaged heart tissue following an acute myocardial infarction (heart attack). The polymer dissolves naturally six weeks after injection, after the heart muscle has strengthened and stabilized.
Published by Globes [online], Israel business news - www.globes-online.com - on March 23, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008